Acute treatment of mania: An update on new medications

Current Psychiatry Reports

Volumn 8, Issue 6, 2006, Pages 504-509

  Gajwani, Prashant ^a   Kemp, David E ^b   Muzina, David J ^b   Xia, Guohua ^b   Gao, Keming ^b   Calabrese, Joseph R ^b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIPARKINSON AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; CHLORPROMAZINE; CLOZAPINE; GABAPENTIN; HALOPERIDOL; LAMOTRIGINE; LITHIUM; MOOD STABILIZER; NEUROLEPTIC AGENT; NEW DRUG; OLANZAPINE; OXCARBAZEPINE; PLACEBO; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; TOPIRAMATE; VALPROATE SEMISODIUM; VALPROIC ACID; ZIPRASIDONE; ZONISAMIDE;

ADD ON THERAPY; AGITATION; AKATHISIA; ASTHENIA; BEHAVIOR DISORDER; CLINICAL TRIAL; DIABETES MELLITUS; DIZZINESS; DROWSINESS; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; DYSPEPSIA; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYNDROME; FOOD AND DRUG ADMINISTRATION; HEADACHE; HOSPITALIZATION; HUMAN; HYPERKINESIA; HYPERLIPIDEMIA; INCREASED APPETITE; INSOMNIA; IRRITABILITY; MANIA; MONOTHERAPY; MOOD DISORDER; MUSCLE HYPOTONIA; NAUSEA; OBESITY; ORTHOSTATIC HYPOTENSION; POLYDIPSIA; POLYURIA; REVIEW; SIDE EFFECT; SOMNOLENCE; SYSTEMATIC REVIEW; TARDIVE DYSKINESIA; TREMOR; UNITED STATES; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

ACUTE DISEASE; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DRUG APPROVAL; DRUG THERAPY, COMBINATION; HUMANS; RANDOMIZED CONTROLLED TRIALS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; VALPROIC ACID;

EID: 33845907401     PISSN: 15233812     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11920-006-0058-3     Document Type: Review

References (41)

1. Angst J: The emerging epidemiology of hypomania and bipolar II disorder. J Affect Disord 1998, 50:143-151.
2. Kessler RC, Chiu WT, Demler O, et al.: Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005, 62:617-627.
3. Calabrese JR, Hirschfeld RM, Reed M, et al.: Impact of bipolar disorder on a U.S. community sample. J Clin Psychiatry 2003, 64:425-432.
4. Ganocy S, Shelton M, Elhaj O, et al.: Predictors of legal involvement in patients with rapid cycling bipolar disorder. In: New Research Program and Abstract of the 159th Annual Meeting of the American Psychiatric Association. Toronto: American Psychiatric Association; 2006:90. Abstract 216.
5. Perlis RH, Welge JA, Vornik LA, et al.: Atypical antipsychotics in treatment of mania: a meta-analysis of randomized, placebo-controlled trials. J Clin Psychiatry 2006, 67:509-516.
6. Hirschfeld RA, Bowdel CL, Gitlin MJ, et al.: Practice guidelines for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002, 159(Suppl 4):1-50.
7. Suppes T, Dennehy EB, Hirschfeld RM, et al.: The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J Clin Psychiatry 2005, 66:870-886.
8. Calabrese JR, Kimmel SE, Woyshville MJ, et al.: Clozapine for treatment-refractory mania. Am J Psychiatry 1996, 153:759-764.
9. Tohen M, Sanger TM, McElroy SL, et al.: Olanzapine versus placebo in the treatment of acute mania. Am J Psychiatry 1999, 156:702-709.
10. Tohen M, Jacobs TG, Grundy SL, et al.: Efficacy of olanzapine in acute bipolar mania: a double blind, placebo-controlled study. Arch Gen Psychiatry 2000, 57:841-849.
11. Hirschfeld RM, Keck PE, Jr, Kramer M, et al.: Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. Am J Psychiatry 2004, 161:1057-1065.
12. Khanna S, Vieta E, Lyons B, et al.: Risperidone in the treatment of acute mania. Br J Psychiatry 2005, 187:229-234.
13. Keck PE, Jr, Marcus R, Tourkodimitris S, et al.: A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 2003, 160:1651-1658.
14. Sachs G, Sanchez R, Marcus R, et al.: Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J Psychopharmacol 2006, 20:536-546.
15. Keck PE, Jr, Versiani M, Potkin S, et al.: Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry 2003, 160:741-748.
16. Potkin SG, Keck PE, Jr, Segal S, et al.: Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial. J Clin Psychopharmacol 2005, 25:301-310.
17. McIntyre RS, Brecher M, Paulsson B, et al.: Quetiapine or haloperidol as monotherapy for bipolar mania - a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial. Eur Neuropsychopharmacol 2005, 15:573-585.
18. Bowden CL, Grunze H, Mullen J, et al.: A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry 2005, 66:111-121.
19. Vieta E, Mullen J, Brecher M, et al.: Quetiapine monotherapy for mania associated with bipolar disorder: combined analysis of two international, double-blind, randomised, placebo-controlled studies. Curr Med Res Opin 2005, 21:923-934.
20. Smulevich AB, Khanna S, Eerdekens M, et al.: Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol. Eur Neuropsychopharmacol 2005, 15:75-84.
21. Tohen M, Goldberg JF, Gonzalez-Pinto Arrillaga AM, et al.: A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. Arch Gen Psychiatry 2003, 60:1218-1226.
22. Vieta E, Bourin M, Sanchez R, et al.: Effectiveness of aripiprazole v. haloperidol in acute bipolar disorder. Br J Psychiatry 2005, 187:235-242.
23. Tohen M, Chengappa KN, Suppes T, et al.: Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry 2002, 59:62-69.
24. Sachs GS, Grossman F, Ghaemi SN, et al.: Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am J Psychiatry 2002, 159:1146-1154.
25. Yatham LN, Grossman F, Augustyns I, et al.: Mood stabilizers plus risperidone or placebo in the treatment of acute mania: international, double-blind, randomized controlled trial. Br J Psychiatry 2003, 182:141-147.
26. Sachs G, Chengappa KN, Suppes T, et al.: Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study. Bipolar Disord 2004, 6:213-223.
27. Ketter TA, Wang PW, Nowakowska C, et al.: Treatment of acute mania in bipolar disorder. In Advances in Treatment of Bipolar Disorder. Review of Psychiatric Series, vol 24, num 3. Edited by Ketter TA. Washington, DC: American Psychiatric Publishing; 2005:11-55.
28. Maggs R: Treatment of manic illness with lithium carbonate. Br J Psychiatry 1969, 109:56-65.
29. Goodwin FK, Murphy DL, Bunney WE, Jr: Lithium-carbonate treatment in depression and mania: a longitudinal double-blind study. Arch Gen Psychiatry 1969, 21:486-496.
30. Pope HG, McElroy SL, Keck PE, et al.: Valproate in treatment of acute mania. A placebo-controlled study. Arch Gen Psychiatry 1991, 48:62-68.
31. Bowden CL, Brugger AM, Swann AN, et al.: Efficacy of divalproex vs lithium and placebo in the treatment of mania. JAMA 1994, 271:918-924.
32. McElroy SL, Keck PE: Pharmacological agents for treatment of acute bipolar mania. Biol Psychiatry 2000, 48:539-557.
33. Weisler RH, Kalali AH, Ketter TA: A multicenter randomized, double-blind, placebo-controlled trial of extended-release carbamazepine capsule as monotherapy for bipolar disorder patients with manic or mixed episodes. J Clin Psychiatry 2004, 65:478-484.
34. Emrich HM: Studies with oxcarbazepine in acute mania. Int Clin Psychopharmacol 1990, 5(Suppl 1):83-88.
35. Kushner SF, Khan A, Lane R, et al.: Topiramate monotherapy in the management of acute mania: results of four double-blind placebo-controlled trials. Bipolar Disord 2006, 8:15-27.
36. Kanba S, Yagi G, Kamijima K, et al.: The first open study of zonisamide, a novel anticonvulsant, shows efficacy in mania. Prog Neuropsychopharmacol Biol Psychiatry 1994, 18:707-715.
37. McElroy SL, Suppes T, Keck PE, et al.: Open-label adjunctive zonisamide in the treatment of bipolar disorder: a prospective trial. J Clin Psychiatry 2005, 66:617-624.
38. Bowden C, Calabrese JR, Ascher J, et al.: Spectrum of efficacy of lamotrigine in bipolar disorder: overview of double-blind placebo controlled study. Paper presented at the 39th Annual Meeting of the American College of Neuropsychopharmacology. San Juan; December 12-15, 2000.
39. Frye MA, Ketter TA, Kimbrell TA, et al.: A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Affect Disord 1998, 48:91-104.
40. Pande AC, Crockatt J, Janney CA, et al.: Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group. Bipolar Disord 2000, 2:249-255.
41. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity: Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004, 27:596-601.